SEARCH

SEARCH BY CITATION

References

  • 1
    Van de Ven P, Mao L, Fogarty A et al. Undetectable viral load is associated with sexual risk taking in HIV serodiscordant gay couples in Sydney. AIDS 2005; 19: 179184.
  • 2
    Guzman R, Buchbinder S, Mansergh G et al. Communication of HIV viral load to guide sexual risk decisions with serodiscordant partners among San Francisco men who have sex with men. AIDS Care 2006; 18: 983989.
  • 3
    Quinn TC, Wawer MJ, Sewankambo N et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med 2000; 342: 921929.
  • 4
    Pereira AS, Smeaton LM, Gerber JG et al. The pharmacokinetics of amprenavir, zidovudine, and lamivudine in the genital tracts of men infected with human immunodeficiency virus type 1 (AIDS Clinical Trials Group Study 850). J Infect Dis 2002; 186: 198204.
  • 5
    Henry K, Chinnock BJ, Quinn RP, Fletcher CV, De Miranda P, Balfour HH Jr. Concurrent zidovudine levels in semen and serum determined by radioimmunoassay in patients with AIDS or AIDS-related complex. JAMA 1988; 259: 30233026.
  • 6
    Chan DJ. Pathophysiology of HIV-1 in semen: current evidence for compartmentalisation and penetration by antiretroviral drugs. Curr HIV Res 2005; 3: 207222.
  • 7
    Taylor S, Pereira AS. Antiretroviral drug concentrations in semen of HIV-1-infected men. Sex Transm Infect 2001; 77: 411.
  • 8
    Lowe SH, Wensing AM, Droste JA et al. No virological failure in semen during properly suppressive antiretroviral therapy despite subtherapeutic local drug concentrations. HIV Clin Trials 2006; 7: 285290.
  • 9
    Lafeuillade A, Solas C, Chadapaud S, Hittinger G, Poggi C, Lacarelle B. HIV-1 RNA levels, resistance, and drug diffusion in semen vs. blood in patients receiving a lopinavir-containing regimen. J Acquir Immune Defic Syndr 2003; 32: 462464.
  • 10
    Lafeuillade A, Solas C, Halfon P, Chadapaud S, Hittinger G, Lacarelle B. Differences in the detection of three HIV-1 protease inhibitors in non-blood compartments: clinical correlations. HIV Clin Trials 2002; 3: 2735.
  • 11
    Winter AJ, Taylor S, Workman J et al. Asymptomatic urethritis and detection of HIV-1 RNA in seminal plasma. Sex Transm Infect 1999; 75: 261263.
  • 12
    Sadiq ST, Taylor S, Copas AJ et al. The effects of urethritis on seminal plasma HIV-1 RNA loads in homosexual men not receiving antiretroviral therapy. Sex Transm Infect 2005; 81: 120123.
  • 13
    Cohen MS, Hoffman IF, Royce RA et al. Reduction of concentration of HIV-1 in semen after treatment of urethritis: implications for prevention of sexual transmission of HIV-1. AIDSCAP Malawi Research Group. Lancet 1997; 349: 18681873.
  • 14
    Taylor S, Sadiq ST, Weller I et al. Drug-resistant HIV-1 in the semen of men receiving antiretroviral therapy with acute sexually transmitted infections. Antivir Ther 2003; 8: 479483.
  • 15
    Sadiq ST, Taylor S, Kaye S et al. The effects of antiretroviral therapy on HIV-1 RNA loads in seminal plasma in HIV-positive patients with and without urethritis. AIDS 2002; 16: 219225.
  • 16
    Grosskurth H, Mosha F, Todd J et al. Impact of improved treatment of sexually transmitted diseases on HIV infection in rural Tanzania: randomised controlled trial. Lancet 1995; 346: 530536.
  • 17
    Moss GB, Overbaugh J, Welch M et al. Human immunodeficiency virus DNA in urethral secretions in men: association with gonococcal urethritis and CD4 cell depletion. J Infect Dis 1995; 172: 14691474.
  • 18
    La Porte C, Back D, Blaschke T et al. Updated guidelines to perform therapeutic drug monitoring for antiretroviral agents. Rev Antivir Ther 2006; 3: 414.
  • 19
    Vernazza PL, Troiani L, Flepp MJ et al. Potent antiretroviral treatment of HIV-infection results in suppression of the seminal shedding of HIV. The Swiss HIV Cohort. AIDS 2000; 14: 117121.
  • 20
    Liuzzi G, Chirianni A, Bagnarelli P, Clementi M, Piazza M. A combination of nucleoside analogues and a protease inhibitor reduces HIV-1 RNA levels in semen: implications for sexual transmission of HIV infection. Antivir Ther 1999; 4: 9599.
  • 21
    Gupta P, Mellors J, Kingsley L et al. High viral load in semen of human immunodeficiency virus type 1-infected men at all stages of disease and its reduction by therapy with protease and nonnucleoside reverse transcriptase inhibitors. J Virol 1997; 71: 62716275.
  • 22
    Celum CL, Buchbinder SP, Donnell D et al. Early human immunodeficiency virus (HIV) infection in the HIV Network for Prevention Trials Vaccine Preparedness Cohort: risk behaviors, symptoms, and early plasma and genital tract virus load. J Infect Dis 2001; 183: 2335.
  • 23
    Mayer KH, Boswell S, Goldstein R et al. Persistence of human immunodeficiency virus in semen after adding indinavir to combination antiretroviral therapy. Clin Infect Dis 1999; 28: 12521259.
  • 24
    Zuckerman RA, Whittington WL, Celum CL et al. Higher concentration of HIV RNA in rectal mucosa secretions than in blood and seminal plasma, among men who have sex with men, independent of antiretroviral therapy. J Infect Dis 2004; 190: 156161.
  • 25
    Medeiros RP, Munerato P, Diaz RS. HIV-1 viral load in blood and semen plasma of Brazilian patients under antiretroviral therapy. J Clin Virol 2004; 30: 346347.
  • 26
    Pinto Neto LF, Vieira NF, Soprani M et al. Longitudinal comparison between plasma and seminal HIV-1 viral loads during antiretroviral treatment. Rev Soc Bras Med Trop 2003; 36: 689694.
  • 27
    La Sala GB, Pilotti E, Nicoli A et al. Dynamics of HIV viral load in blood and semen of patients under HAART: impact of therapy in assisted reproduction procedures. AIDS 2007; 21: 377379.
  • 28
    Eron JJ Jr., Smeaton LM, Fiscus SA et al. The effects of protease inhibitor therapy on human immunodeficiency virus type 1 levels in semen (AIDS Clinical Trials Group Protocol 850). J Infect Dis 2000; 181: 16221628.
  • 29
    Bujan L, Daudin M, Matsuda T et al. Factors of intermittent HIV-1 excretion in semen and efficiency of sperm processing in obtaining spermatozoa without HIV-1 genomes. AIDS 2004; 18: 757766.
  • 30
    Leruez-Ville M, Dulioust E, Costagliola D et al. Decrease in HIV-1 seminal shedding in men receiving highly active antiretroviral therapy: an 18 month longitudinal study (ANRS EP012). AIDS 2002; 16: 486488.
  • 31
    Barroso PF, Schechter M, Gupta P, Bressan C, Bomfim A, Harrison LH. Adherence to antiretroviral therapy and persistence of HIV RNA in semen. J Acquir Immune Defic Syndr 2003; 32: 435440.
  • 32
    Fiore JR, Suligoi B, Saracino A et al. Correlates of HIV-1 shedding in cervicovaginal secretions and effects of antiretroviral therapies. AIDS 2003; 17: 21692176.
  • 33
    Lampinen TM, Critchlow CW, Kuypers JM et al. Association of antiretroviral therapy with detection of HIV-1 RNA and DNA in the anorectal mucosa of homosexual men. AIDS 2000; 14: F69F75.
  • 34
    Kiessling AA, Fitzgerald LM, Zhang D et al. Human immunodeficiency virus in semen arises from a genetically distinct virus reservoir. AIDS Res Hum Retroviruses 1998; 14 (Suppl 1): 3341.
  • 35
    Vernazza P, Hirschel B, Bernasconi E, Flepp M. HIV-positive individuals without sexually transmitted diseases (STD) and on effective antiretroviral therapy are sexually non-infectious. Bull Médecins Suisses 2008; 89: 5.